BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24300182)

  • 1. Atomic pairwise distribution function analysis of the amorphous phase prepared by different manufacturing routes.
    Boetker JP; Koradia V; Rades T; Rantanen J; Savolainen M
    Pharmaceutics; 2012 Jan; 4(1):93-103. PubMed ID: 24300182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of Process Induced Disorder in Milled Samples Using Different Analytical Techniques.
    Zimper U; Aaltonen J; McGoverin CM; Gordon KC; Krauel-Goellner K; Rades T
    Pharmaceutics; 2010 Feb; 2(1):30-49. PubMed ID: 27721341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid-state characterization of amorphous and mesomorphous calcium ketoprofen.
    Atassi F; Mao C; Masadeh AS; Byrn SR
    J Pharm Sci; 2010 Sep; 99(9):3684-97. PubMed ID: 19780126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic form of piroxicam influences the performance of amorphous material prepared by ball-milling.
    Naelapää K; Boetker JP; Veski P; Rantanen J; Rades T; Kogermann K
    Int J Pharm; 2012 Jun; 429(1-2):69-77. PubMed ID: 22433471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of crystalline disorder in cryo-milled samples of indomethacin using atomic pair-wise distribution functions.
    Bøtker JP; Karmwar P; Strachan CJ; Cornett C; Tian F; Zujovic Z; Rantanen J; Rades T
    Int J Pharm; 2011 Sep; 417(1-2):112-9. PubMed ID: 21182911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy.
    Savolainen M; Kogermann K; Heinz A; Aaltonen J; Peltonen L; Strachan C; Yliruusi J
    Eur J Pharm Biopharm; 2009 Jan; 71(1):71-9. PubMed ID: 18590816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward understanding the evolution of griseofulvin crystal structure to a mesophase after cryogenic milling.
    Feng T; Bates S; Carvajal MT
    Int J Pharm; 2009 Feb; 367(1-2):16-9. PubMed ID: 19013224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of sample characteristics on quantification of carbamazepine hydrate formation by X-ray powder diffraction and Raman spectroscopy.
    Tian F; Zhang F; Sandler N; Gordon KC; McGoverin CM; Strachan CJ; Saville DJ; Rades T
    Eur J Pharm Biopharm; 2007 Jun; 66(3):466-74. PubMed ID: 17257816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin.
    Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
    Eur J Pharm Biopharm; 2012 Feb; 80(2):459-64. PubMed ID: 22019529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods.
    Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
    Int J Pharm; 2011 Sep; 417(1-2):94-100. PubMed ID: 21182910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for differences in the amorphous state of indomethacin using multivariate visualization.
    Savolainen M; Heinz A; Strachan C; Gordon KC; Yliruusi J; Rades T; Sandler N
    Eur J Pharm Sci; 2007 Feb; 30(2):113-23. PubMed ID: 17169536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. X-ray powder diffractometry in combination with principal component analysis--a tool for monitoring solid state changes.
    Kogermann K; Veski P; Rantanen J; Naelapää K
    Eur J Pharm Sci; 2011 Jul; 43(4):278-89. PubMed ID: 21575718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the Microstructure of Amorphous Silica Nanostructures Using High-Resolution Electron Microscopy, Electron Energy Loss Spectroscopy, X-ray Powder Diffraction, and Electron Pair Distribution Function.
    Khouchaf L; Boulahya K; Das PP; Nicolopoulos S; Kis VK; Lábár JL
    Materials (Basel); 2020 Oct; 13(19):. PubMed ID: 33019776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unravelling the relationship between degree of disorder and the dissolution behavior of milled glibenclamide.
    Mah PT; Laaksonen T; Rades T; Aaltonen J; Peltonen L; Strachan CJ
    Mol Pharm; 2014 Jan; 11(1):234-42. PubMed ID: 24224572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative solid-state analysis of three solid forms of ranitidine hydrochloride in ternary mixtures using Raman spectroscopy and X-ray powder diffraction.
    Chieng N; Rehder S; Saville D; Rades T; Aaltonen J
    J Pharm Biomed Anal; 2009 Jan; 49(1):18-25. PubMed ID: 19081220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1.
    Chieng N; Zujovic Z; Bowmaker G; Rades T; Saville D
    Int J Pharm; 2006 Dec; 327(1-2):36-44. PubMed ID: 16949221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds.
    Patterson JE; James MB; Forster AH; Lancaster RW; Butler JM; Rades T
    J Pharm Sci; 2005 Sep; 94(9):1998-2012. PubMed ID: 16052554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relating hydrogen-bonding interactions with the phase behavior of naproxen/PVP K 25 solid dispersions: evaluation of solution-cast and quench-cooled films.
    Paudel A; Nies E; Van den Mooter G
    Mol Pharm; 2012 Nov; 9(11):3301-17. PubMed ID: 23009610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the solid-state properties of crystalline lysozyme during pharmaceutical unit-operations.
    Mohammad MA; Grimsey IM; Forbes RT
    J Pharm Biomed Anal; 2015 Oct; 114():176-83. PubMed ID: 26068908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation and physical stability of the amorphous phase of ranitidine hydrochloride polymorphs prepared by cryo-milling.
    Chieng N; Rades T; Saville D
    Eur J Pharm Biopharm; 2008 Mar; 68(3):771-80. PubMed ID: 17945474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.